Word: coxing
(lookup in dictionary)
(lookup stats)
Dates: during 2000-2009
Sort By: most recent first
(reverse)
DiCicco still has a long way to go. He has identified a group of interested potential owners--including old hands Hendricks, cable baron Amos Hostetter and Cox chairman Jim Kennedy--but none have made any commitments. Nor have any advertisers. McDonald's, Coca-Cola, apparel maker Under Armour and Deutsche Bank sponsored WUSA exhibition festivals in Los Angeles and Minneapolis, Minn., this summer, but as McDonald's marketing executive John Lewicki puts it, "We're in wait-and-see mode...
...WORLD IN WHICH THE FORTUNE OF a pharmaceutical company can rise and fall on the strength of a handful of blockbuster drugs, Vioxx was a giant. Unveiled with great fanfare by Merck in 1999, it was part of a group of prescription medicines called COX-2 inhibitors that were supposed to be safer for treating arthritis pain than over-the-counter remedies like aspirin, ibuprofen and naproxen. Thanks to an aggressive, multimillion-dollar marketing campaign, more than 20 million Americans took Vioxx at least once. The drug racked up $2.5 billion in worldwide sales last year and accounted...
...recall also raised long-simmering doubts about the benefits of the whole class of COX-2 inhibitors. These so-called designer drugs, which include Celebrex and a newer drug called Bextra, were supposed to offer the pain-killing power of aspirin without the damage to the stomach lining. But they were a lot more expensive than over-the-counter pain-killers (prescriptions cost as much as $2 to $3 a day), and many doctors felt the drugs were being hyped far beyond their medical value. "These agents have been the subject of absolutely intensive, unrelenting marketing," Wofsy says. Even...
...none of the other COX-2 inhibitors have been tarred with Vioxx's brush. Pfizer's Celebrex has been studied the longest; some patients in three ongoing Celebrex trials have been followed for several years without any signs of cardiovascular effects. Bextra, also from Pfizer, hasn't been tested as long, but so far the data look good. Two more COX-2 inhibitors, Arcoxia (from Merck) and Prexige (from Novartis), are awaiting FDA approval. "Obviously, we now have to look more carefully at the other members of the class," says Dr. Steven Nissen, a cardiologist at the Cleveland Clinic...
...meantime, don't assume you necessarily have to switch to another COX-2 inhibitor. Aspirin, ibuprofen and naproxen work just as well as the prescription drugs, provided that you are not at increased risk for bleeding, peptic ulcer or other gastrointestinal problems. (See box for more details...